Egaptivon pegol

Drug Profile

Egaptivon pegol

Alternative Names: ARC1779

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Archemix Corporation
  • Class Antithrombotics; Nucleotide aptamers; Polyethylene glycols
  • Mechanism of Action Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemolytic uraemic syndrome; Thrombosis; Thrombotic thrombocytopenic purpura; Von Willebrand disease

Most Recent Events

  • 12 Feb 2010 A phase IIa trial in cerebral embolism discontinued because of slow enrolment
  • 31 Mar 2009 Archemix initiates enrolment in a phase IIa trial for thrombosis prevention (in patients undergoing carotid endarterectomy) in Europe and North America
  • 28 Jan 2009 Phase-II clinical trials in Haemolytic uraemic syndrome in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top